OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
K.N. Chi, Shahneen Sandhu, Matthew R. Smith, et al.
Annals of Oncology (2023) Vol. 34, Iss. 9, pp. 772-782
Open Access | Times Cited: 104
K.N. Chi, Shahneen Sandhu, Matthew R. Smith, et al.
Annals of Oncology (2023) Vol. 34, Iss. 9, pp. 772-782
Open Access | Times Cited: 104
Showing 1-25 of 104 citing articles:
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M.F. Mosele, C. Benedikt Westphalen, A Stenzinger, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 588-606
Open Access | Times Cited: 89
M.F. Mosele, C. Benedikt Westphalen, A Stenzinger, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 588-606
Open Access | Times Cited: 89
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Derya Tilki, Roderick C.N. van den Bergh, Erik Briers, et al.
European Urology (2024) Vol. 86, Iss. 2, pp. 164-182
Closed Access | Times Cited: 79
Derya Tilki, Roderick C.N. van den Bergh, Erik Briers, et al.
European Urology (2024) Vol. 86, Iss. 2, pp. 164-182
Closed Access | Times Cited: 79
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Karim Fizazi, Arun Azad, Nobuaki Matsubara, et al.
Nature Medicine (2023) Vol. 30, Iss. 1, pp. 257-264
Open Access | Times Cited: 61
Karim Fizazi, Arun Azad, Nobuaki Matsubara, et al.
Nature Medicine (2023) Vol. 30, Iss. 1, pp. 257-264
Open Access | Times Cited: 61
Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes
David Olmos, David Lorente, Daniel Alameda, et al.
Annals of Oncology (2024) Vol. 35, Iss. 5, pp. 458-472
Open Access | Times Cited: 21
David Olmos, David Lorente, Daniel Alameda, et al.
Annals of Oncology (2024) Vol. 35, Iss. 5, pp. 458-472
Open Access | Times Cited: 21
Development of PARP inhibitors in advanced prostate cancer
María T. Bourlon, Paola Valdez, Elena Castro
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 20
María T. Bourlon, Paola Valdez, Elena Castro
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 20
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Silke Gillessen, Fabio Turco, Ian D. Davis, et al.
European Urology (2024)
Open Access | Times Cited: 16
Silke Gillessen, Fabio Turco, Ian D. Davis, et al.
European Urology (2024)
Open Access | Times Cited: 16
Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis
Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz, Arifa Bibi, et al.
European Urology (2025)
Closed Access | Times Cited: 2
Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz, Arifa Bibi, et al.
European Urology (2025)
Closed Access | Times Cited: 2
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 19, pp. 4318-4328
Closed Access | Times Cited: 15
Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 19, pp. 4318-4328
Closed Access | Times Cited: 15
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Tivya Kulasegaran, Niara Oliveira
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 7, pp. 914-931
Open Access | Times Cited: 12
Tivya Kulasegaran, Niara Oliveira
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 7, pp. 914-931
Open Access | Times Cited: 12
PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape
Ashaar Al-Akhras, Chadi Hage Chehade, Arshit Narang, et al.
Life (2024) Vol. 14, Iss. 2, pp. 198-198
Open Access | Times Cited: 10
Ashaar Al-Akhras, Chadi Hage Chehade, Arshit Narang, et al.
Life (2024) Vol. 14, Iss. 2, pp. 198-198
Open Access | Times Cited: 10
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations
Joseph J. Park, Alec Chu, Jinju Li, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 8
Joseph J. Park, Alec Chu, Jinju Li, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 8
The Landscape of PARP Inhibitors in Solid Cancers
Marta Muzzana, Massimo Broggini, Giovanna Damia
OncoTargets and Therapy (2025) Vol. Volume 18, pp. 297-317
Open Access | Times Cited: 1
Marta Muzzana, Massimo Broggini, Giovanna Damia
OncoTargets and Therapy (2025) Vol. Volume 18, pp. 297-317
Open Access | Times Cited: 1
Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer
Urbano Anido, O. Fernández-Calvo, Juan Ruiz‐Bañobre, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
Urbano Anido, O. Fernández-Calvo, Juan Ruiz‐Bañobre, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients
Heather H. Cheng, Jeffrey Shevach, Elena Castro, et al.
JAMA Oncology (2024) Vol. 10, Iss. 9, pp. 1272-1272
Closed Access | Times Cited: 6
Heather H. Cheng, Jeffrey Shevach, Elena Castro, et al.
JAMA Oncology (2024) Vol. 10, Iss. 9, pp. 1272-1272
Closed Access | Times Cited: 6
Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review
Edoardo Francini, Neeraj Agarwal, Elena Castro, et al.
European Urology (2024) Vol. 87, Iss. 1, pp. 29-46
Closed Access | Times Cited: 5
Edoardo Francini, Neeraj Agarwal, Elena Castro, et al.
European Urology (2024) Vol. 87, Iss. 1, pp. 29-46
Closed Access | Times Cited: 5
A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors
Chadi Hage Chehade, Georges Gebrael, Nicolas Sayegh, et al.
CA A Cancer Journal for Clinicians (2025)
Open Access
Chadi Hage Chehade, Georges Gebrael, Nicolas Sayegh, et al.
CA A Cancer Journal for Clinicians (2025)
Open Access
Empowering PARP inhibition through rational combination: Mechanisms of PARP inhibitors and combinations with a focus on the treatment of metastatic castration-resistant prostate cancer
Jinge Zhao, Bo Tang, Pengfei Shen, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104698-104698
Closed Access
Jinge Zhao, Bo Tang, Pengfei Shen, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104698-104698
Closed Access
Deciphering the mechanisms of PARP inhibitor resistance in prostate cancer: Implications for precision medicine
Cheng Wang, Xiaoran Han, Shaoqiu Kong, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 185, pp. 117955-117955
Closed Access
Cheng Wang, Xiaoran Han, Shaoqiu Kong, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 185, pp. 117955-117955
Closed Access
Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value
Fan Yu, Zhenhua Liu, Yuke Chen, et al.
Advances in Therapy (2024) Vol. 41, Iss. 6, pp. 2196-2216
Open Access | Times Cited: 4
Fan Yu, Zhenhua Liu, Yuke Chen, et al.
Advances in Therapy (2024) Vol. 41, Iss. 6, pp. 2196-2216
Open Access | Times Cited: 4
PARP inhibitors in prostate cancers, is it time for combinations?
Diego Teyssonneau, Charles Dariane, Éric Barret, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 4
Diego Teyssonneau, Charles Dariane, Éric Barret, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 4
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Louise Kostos, Ben Tran, Arun Azad
Drugs (2024) Vol. 84, Iss. 9, pp. 1093-1109
Open Access | Times Cited: 4
Louise Kostos, Ben Tran, Arun Azad
Drugs (2024) Vol. 84, Iss. 9, pp. 1093-1109
Open Access | Times Cited: 4
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)
Andrew J. Armstrong, Amy K. Taylor, Michael Haffner, et al.
Prostate Cancer and Prostatic Diseases (2024)
Open Access | Times Cited: 4
Andrew J. Armstrong, Amy K. Taylor, Michael Haffner, et al.
Prostate Cancer and Prostatic Diseases (2024)
Open Access | Times Cited: 4
Talazoparib Plus Enzalutamide in Hrr-Deficient Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Results from the Phase 3 Talapro-2 Trial
Karim Fizazi, Arun Azad, Nobuaki Matsubara, et al.
(2025)
Closed Access
Karim Fizazi, Arun Azad, Nobuaki Matsubara, et al.
(2025)
Closed Access
PARP inhibitor‐based treatment in metastatic, castration‐resistant prostate cancer (mCRPC): A systematic review and meta‐analysis
Michela Roberto, Mattia Alberto Di Civita, Daniele Marinelli, et al.
BJUI Compass (2025) Vol. 6, Iss. 1
Open Access
Michela Roberto, Mattia Alberto Di Civita, Daniele Marinelli, et al.
BJUI Compass (2025) Vol. 6, Iss. 1
Open Access
NGS-basierte („next generation sequencing“) molekulare Panelanalyse des metastasierten Prostatakarzinoms: Wie häufig finden wir therapierbare Mutationen?
Olivia Steenbock, Pia Paffenholz, Constantin Rieger, et al.
Deleted Journal (2025)
Open Access
Olivia Steenbock, Pia Paffenholz, Constantin Rieger, et al.
Deleted Journal (2025)
Open Access
